Patients with severe combined immunodeficiency treated in the newborn period Nine had donor B cells, 13 remained on immunoglobulin treatment and seven had discontinued immunoglobulin and made specific antibodies in response to vaccination. Three had severe (grade III-IV) graftversus-host disease (GvHD); resolution occurred in two with treatment. A third required liver transplantation but the patient now is a complete haematopoietic chimera with normal liver function.
Our own series has now extended to 20 patients with 5 months-11 years follow-up (Table 1 ). All survived and have donor T-cell chimerism. In all, 18 underwent myeloablative chemotherapy and 15 received T-cell-depleted haematopoietic stem cells. In all, 13 have made specific antibody to vaccine antigen and one is currently being evaluated. Six remain on IVIG; two are less than 6 months post-BMT, two received Rituximab for B-lymphoproliferative disease secondary to EBV and have no B cells and one was treated for prolonged GvHD with autoimmune Guillan-Barre syndrome and remains on intravenous immunoglobulin and one patient does not make any antibody. Two patients have had significant bacterial infections post transplantation; one osteomyelitis and one retropharyngeal abscess, both treated successfully. Two patients had significant GvHD; one has complete resolution, the second is on a reducing course of immunosuppression.
For in utero transplantation to be considered, the gene defect within the family needs to be previously identified in order that chorionic villus sampling can be used for diagnostic purposes. Alternatively, cordocentesis performed at 18 weeks gestation will allow the diagnosis to be made on foetal lymphocyte phenotype. Both of these procedures carry a small but significant risk of foetal loss, in the order of 1-2% in experienced centres, but potentially of an unaffected infant. Benefits of in utero transplantation for SCID are stated as including T-cell reconstitution before birth, with no postnatal period of susceptibility to infection. 4 However, the T-cell lymphopenia with diminished mitogen response reported after some in utero transplantation procedures leaves the patient at risk of opportunistic infection. 5, 6 Furthermore, occult maternofoetal T-cell engraftment, common in many SCID patients 7 may lead to rejection of the graft, and the use of maternal stem cells harvested during pregnancy is unlikely. GvHD is undetectable in utero, and treatment with immunosuppression, administered via the mother is impractical, and the foetus cannot be monitored. The results of in utero transplantation for SCID, the most successful of procedures for which in utero transplantation has been attempted show a survival rate of only 64% 1 compared with 98% for neonatal transplant series. It is not clear from the data presented how many of those transplanted in utero have complete immune reconstitution with functioning humoral immunity.
We recognise that in conditions such as metabolic disease, for which in utero transplantation has not yet been successful, very early prenatal diagnosis and treatment may prevent damage, and in utero transplantation may have a role in management. However, given the current excellent results of early neonatal transplantation for SCID, we believe that in utero transplantation has no place in the treatment of these conditions at present. We would suggest that the current practice of diagnosis at birth, followed by prompt referral to a specialist centre where full isolation facilities are available and stem cell transplantation can take place, currently is the safest form of treatment for patients with SCID in whom there is already a family diagnosis.
